We are excited to announce the official launch of a Phase 1 clinical trial of Treg cell therapy for Amyotrophic Lateral Sclerosis (ALS), sponsored by NovaBio Therapeutics, at the prestigious Tiantan H...
We are proud to announce the successful completion of our Series B financing, led by Taikun Fund, one of the largest life science investment funds in China, with participation from multiple well-known...
Client OverviewBioGene-X is a leading gene editing therapeutics company in China, driven by cutting-edge gene editing technology and dedicated to pioneering innovative treatments. The company was ...
GCP ClinPlus delivered comprehensive biostatistical services for an innovative oral targeted therapy inhibiting cancer cell proliferation, specifically developed for chronic lymphocytic leukemia ...
Record-Breaking Innovation in Chinese PharmaceuticalsChina's pharmaceutical landscape is experiencing unprecedented growth, with the National Medical Products Administration (NMPA) recently report...
Executive SummaryGCP ClinPlus successfully delivered comprehensive clinical research services that led to the groundbreaking approval of China's first stem cell therapy for acute Graft-versus-Host...
